<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS199091</article-id><article-id pub-id-type="doi">10.1101/2024.09.27.615320</article-id><article-id pub-id-type="archive">PPR917425</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Abnormal vasculature reduces overlap between drugs and oxygen in a tumour computational model: implications for therapeutic efficacy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Enjalbert</surname><given-names>Romain</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Köry</surname><given-names>Jakub</given-names></name><xref ref-type="aff" rid="A2">2</xref><xref ref-type="fn" rid="FN1">†</xref></contrib><contrib contrib-type="author"><name><surname>Krüger</surname><given-names>Timm</given-names></name><xref ref-type="aff" rid="A3">3</xref><xref ref-type="fn" rid="FN2">a</xref><xref ref-type="corresp" rid="CR1">b</xref></contrib><contrib contrib-type="author"><name><surname>Bernabeu</surname><given-names>Miguel O.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="fn" rid="FN2">a</xref><xref ref-type="corresp" rid="CR1">b</xref></contrib></contrib-group><aff id="A1"><label>1</label>Centre for Medical Informatics, Usher Institute, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01nrxwf90</institution-id><institution>The University of Edinburgh</institution></institution-wrap>, <city>Edinburgh</city><postal-code>EH16 4UX</postal-code>, <country country="GB">United Kingdom</country></aff><aff id="A2"><label>2</label>School of Mathematics and Statistics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00vtgdb53</institution-id><institution>University of Glasgow</institution></institution-wrap>, <city>Glasgow</city><postal-code>G12 8QQ</postal-code>, <country country="GB">United Kingdom</country></aff><aff id="A3"><label>3</label>School of Engineering, Institute for Multiscale Thermofluidics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01nrxwf90</institution-id><institution>The University of Edinburgh</institution></institution-wrap>, <city>Edinburgh</city><postal-code>EH9 3FD</postal-code>, <country country="GB">United Kingdom</country></aff><author-notes><corresp id="CR1"><label>b</label> Corresponding authors: <email>timm.krueger@ed.ac.uk</email>, <email>miguel.bernabeu@ed.ac.uk</email></corresp><fn id="FN1"><label>†</label><p id="P1">Deceased 3 May 2024</p></fn><fn id="FN2" fn-type="equal"><label>a</label><p id="P2">Equally contributing senior authors</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>01</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="preprint"><day>29</day><month>09</month><year>2024</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P3">The tumour microvasculature is abnormal, and as a consequence oxygen and drug transport to the tumour tissue is impaired. The abnormal microvasculature contributes to tumour tissue hypoxia, as well as to varying drug penetration depth in the tumour. Many anti-cancer treatments require the presence of oxygen to be fully efficacious, however the question of how well oxygen concentration overlaps with drug concentration is not elucidated, which could compromise the therapeutic effect of these drugs. In this work we use a computational model of blood flow and oxygen transport, and develop a model for an oxygen-dependent drug, T-DM1, to study the overlap of oxygen and drug concentration in healthy and tumour tissue, where we assume the tumour tissue to compress blood vessels. Our results show that, due to the compressed vessels present in tumours, areas of sufficient oxygen concentration for a drug to function overlap poorly with areas of sufficient drug concentration, covering 28% of the tumour tissue, compared to 82% in healthy tissue. The reduction in drug and oxygen overlap is due to the altered red blood cell dynamics through the abnormal microvasculature, and indicates that drug transport to tumours should not be considered independently of oxygen transport in cases where the drug requires oxygen to function.</p></abstract></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P4">The abnormal tumour microenvironment (TME) is a hallmark of cancer [<xref ref-type="bibr" rid="R1">1</xref>]. The TME impairs drug delivery to tumour tissue and increases tumour tissue hypoxia, both barriers to the clinical efficacy of drugs [<xref ref-type="bibr" rid="R2">2</xref>–<xref ref-type="bibr" rid="R4">4</xref>].</p><p id="P5">Pharmacokinetics is an important aspect of the clinical efficacy of a drug [<xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R6">6</xref>]. Drugs are first transported through the blood stream and then extravasate to the tumour tissue [<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R8">8</xref>]. Following extravasation, the advection, diffusion and reaction kinetics of the drug determine its transport to tumour tissue [<xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R6">6</xref>]. The TME can act as a barrier to drug delivery to the tissue and therefore to its efficacy [<xref ref-type="bibr" rid="R5">5</xref>, <xref ref-type="bibr" rid="R9">9</xref>]. However, the presence of a drug can be insufficient to fully determine a drugs efficacy, as recent studies have shown that the cytotoxicity of some drugs may also be reduced by the absence of oxygen [<xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R10">10</xref>–<xref ref-type="bibr" rid="R13">13</xref>]. As an example, the efficacy of trastuzumab-emtansine (T-DM1), a drug used to treat HER2+ breast cancer, is reduced under hypoxic conditions due to caveolin-1 translocation [<xref ref-type="bibr" rid="R10">10</xref>], making the transport of oxygen to tumour tissue of particular relevance for the efficacy of such drugs.</p><p id="P6">Oxygen travels bound to red blood cells through microvascular networks prior to being delivered to the tissue [<xref ref-type="bibr" rid="R14">14</xref>]. In microvascular networks, red blood cells partition unevenly at microvascular bifurcations [<xref ref-type="bibr" rid="R15">15</xref>]. Previous work has shown that in networks with tumour vascular abnormalities [<xref ref-type="bibr" rid="R16">16</xref>], such as reduced inter-bifurcation distances [<xref ref-type="bibr" rid="R17">17</xref>] and vessel compression [<xref ref-type="bibr" rid="R18">18</xref>, <xref ref-type="bibr" rid="R19">19</xref>], the partitioning of red blood cells at bifurcations is abnormal, leading to a high heterogeneity of discharge haematocrit (flowrate fraction of red blood cells in blood) [<xref ref-type="bibr" rid="R17">17</xref>–<xref ref-type="bibr" rid="R20">20</xref>]. As a consequence of haematocrit heterogeneity, blood vessels are inefficient at delivering oxygen and tumour tissue can be hypoxic [<xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R21">21</xref>–<xref ref-type="bibr" rid="R24">24</xref>]. In addition, tumour microvascular networks can have avascular areas that lead to hypoxic regions due to the limited diffusion distance of oxygen [<xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R26">26</xref>].</p><p id="P7">In cases where a drug requires oxygen to function, the question of the overlap of drug and oxygen concentration for full therapeutic effect needs to be considered. Since oxygen and drugs are transported via different mechanisms, we hypothesise that, in the abnormal tumour microvasculature, areas of high oxygen concentration can overlap poorly with areas of high drug concentration, and that this hypothesis is relevant given the oxygen requirements of some drugs for them to be efficacious. We investigate this hypothesis in a computational model of a tumour with tumour induced compressed vessels,[<xref ref-type="bibr" rid="R27">27</xref>] blood flow [<xref ref-type="bibr" rid="R18">18</xref>], oxygen transport [<xref ref-type="bibr" rid="R17">17</xref>] and T-DM1 transport [<xref ref-type="bibr" rid="R7">7</xref>], where the computational model is used as an exemplar to illustrate how the different mechanisms of transport lead to poor overlap between oxygen and drug concentration in the tissue.</p><p id="P8">Our results show that, due to the abnormal vascular structures present in tumours (vessel compression in our computational model), areas of sufficient oxygen concentration for a drug to function overlap poorly with areas of sufficient drug concentration. This effect is mostly due to the poor oxygen transport to the tumour tissue, and indicates that drug transport should not be considered independently of oxygen transport in cases where the drug requires oxygen to function. These findings provide a theoretical underpinning for therapeutic approaches aimed at enhancing tumour oxygenation in order to improve anticancer drug efficacy.</p></sec><sec id="S2" sec-type="methods"><title>Methods</title><sec id="S3"><title>Tumour and control models</title><p id="P9">To test our hypothesis, we generate a tumour model and a control model to compare the two. In both models, the same microvascular network is used, illustrated in <xref ref-type="fig" rid="F1">Figure 1a</xref>, and generated using the open-source Tumorcode software [<xref ref-type="bibr" rid="R28">28</xref>]. The code employs a set of rules based on Murray’s law and the properties of venules, arterioles and capillaries to generate a microvascular network on a mesh with properties matching real network sample [<xref ref-type="bibr" rid="R29">29</xref>]. The settings we use to generate the network are the default two-dimensional network generator with a single inlet and a single outlet in a 5000 <italic>μm</italic> by 5000 <italic>μm</italic> square domain. We separate the microvascular network into periphery and core vessels, shown in <xref ref-type="fig" rid="F1">Figure 1a</xref>, where core vessels are defined as having both ends of the vessel within 1000 <italic>μm</italic> of the centre of the network [<xref ref-type="bibr" rid="R18">18</xref>], the remaining vessels are periphery vessels. In the tumour model, the core vessels are compressed but not the periphery ones, while in the control model none of the vessels are compressed.</p></sec><sec id="S4"><title>Blood flow</title><p id="P10">In this work, we treat blood flow as a one-dimensional continuous fluid, imposing Poiseuille’s law at every vessel segment [<xref ref-type="bibr" rid="R15">15</xref>]. In addition, we use existing models to implement the Fåhraeus effect, Fahraeus-Lindqvist effect, and phase separation at bifurcations in our treatment of blood flow [<xref ref-type="bibr" rid="R30">30</xref>–<xref ref-type="bibr" rid="R32">32</xref>]. In addition, we consider some blood vessels to be compressed, and in those cases treat vessel-cross sections as elliptical (with an aspect ratio of 4.26 [<xref ref-type="bibr" rid="R27">27</xref>]) and use a modified phase-separation model for red blood cell partitioning at bifurcations [<xref ref-type="bibr" rid="R18">18</xref>]. The networks were chosen to have a single inlet and a single outlet, facilitating the choice of boundary conditions as they do not affect the distribution of discharge haematocrit in the network, therefore an arbitrary pressure value is imposed at the inlet, and a 0 value at the outlet. Unless stated otherwise, the inlet discharge haematocrit to the network is 30% [<xref ref-type="bibr" rid="R33">33</xref>]. The <xref ref-type="supplementary-material" rid="SD1">supplementary material</xref> contains the full details of the blood flow model.</p></sec><sec id="S5"><title>Oxygen and drug transport</title><p id="P11">Vascular networks are embedded inside a rectangular domain representing the tissue through which oxygen and T-DM1 diffuse. Both chemical species are uptaken by the tissue and are supplied by vessels acting as line sources with strength proportional to local vessel diameter thus perfusing the tissue.</p><p id="P12">The oxygen transport problem is governed by the same equation and parameters as described in <xref ref-type="supplementary-material" rid="SD1">Supplementary material</xref> to [<xref ref-type="bibr" rid="R17">17</xref>] and the numerical simulations are performed in Microvessel Chaste [<xref ref-type="bibr" rid="R34">34</xref>]. Here, by focussing on the long-time behaviour we adopt a quasi-steady state approximation [<xref ref-type="bibr" rid="R35">35</xref>]. Mathematically, the problem thus reduces to a steady reaction-diffusion equation <disp-formula id="FD1"><label>(1)</label><mml:math id="M1"><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>x</mml:mi><mml:mi>y</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mo>∇</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>x</mml:mi><mml:mi>y</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>π</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>0.45</mml:mn></mml:mrow></mml:mfrac><mml:msub><mml:mi>H</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>x</mml:mi><mml:mi>y</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi><mml:mi>w</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mi>κ</mml:mi><mml:msub><mml:mi>c</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mi>x</mml:mi><mml:mi>y</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mtext>,</mml:mtext></mml:math></disp-formula> where <italic>D<sub>oxygen</sub></italic> is the diffusion coefficient for oxygen in the tissue, <italic>c<sub>oxygen</sub></italic> is the oxygen concentration in the tissue, <italic>γ</italic> is the vessel permeability, <italic>d<sub>l</sub></italic> is the local vessel diameter, <italic>H<sub>l</sub></italic> is the local vessel discharge haematocrit, <italic>β<sub>ref</sub></italic> relates the discharge haematocrit in the vessel to an oxygen concentration in the vessel, <italic>κ</italic> is the rate at which oxygen is consumed by the cells, and <italic>δ<sub>newtork</sub></italic> is a representation of the vessel network via a collection of Dirac delta function sources [<xref ref-type="bibr" rid="R17">17</xref>]. The majority of the governing parameters are taken from [<xref ref-type="bibr" rid="R36">36</xref>], while the haematocrit term is taken from the blood flow simulations described in the Blood Flow section.</p><p id="P13">For the tissue dynamics of T-DM1, one must typically distinguish between three distinct phases of the drug – free, bound and internalized – and model transitions between these phases. Our starting point is the model from [<xref ref-type="bibr" rid="R7">7</xref>]. Free drug (concentration <italic>C</italic>) diffuses in the tissue with a diffusion constant <italic>D</italic> and is supplied by the vessels at a rate proportional to the plasma concentration <italic>C</italic><sub>plasma</sub> (which decays in time due to depletion of drug from the blood stream, more details to follow in this section). Simultaneously, the free drug binds to receptors embedded in cell membranes (supplied at a fixed concentration <italic>C<sub>r</sub></italic> for simplicity) to form bound complexes (concentration <italic>B</italic>) with a rate constant <italic>k</italic><sub>on</sub> and unbinds from these complexes at a rate <italic>k</italic><sub>off</sub>. Drug in bound complexes is thus immobilized (cannot further penetrate the tissue) and internalized (concentration <italic>I</italic>) at a rate <italic>k</italic><sub>int</sub>. As trastuzumab is a monoclonal antibody, we assume no binding to blood cells or plasma proteins occurs (<italic>f<sub>free</sub></italic> = 1 holds for the free-drug fraction from [<xref ref-type="bibr" rid="R5">5</xref>]). The full dimensional model for T-DM1 kinetics then reads <disp-formula id="FD2"><label>(2)</label><mml:math id="M2"><mml:mtable columnalign="left"><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>D</mml:mi><mml:msup><mml:mo>∇</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:mi>C</mml:mi><mml:mo>+</mml:mo><mml:mi>π</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mspace width="0.2em"/><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mtext>plasma</mml:mtext></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mfrac><mml:mi>C</mml:mi><mml:mi>ε</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mtext>network</mml:mtext></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:mi>C</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow><mml:mi>ε</mml:mi></mml:mfrac><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub><mml:mi>B</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:mi>C</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow><mml:mi>ε</mml:mi></mml:mfrac><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub><mml:mi>B</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>int</mml:mtext></mml:mrow></mml:msub><mml:mi>B</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>int</mml:mtext></mml:mrow></mml:msub><mml:mi>B</mml:mi><mml:mtext>,</mml:mtext></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula> where <italic>d<sub>l</sub></italic> is the local vessel diameter, <italic>ε</italic> is the effective void fraction, <italic>P</italic> the vessel permeability and <italic>δ</italic><sub>network</sub> is a representation of the vessel network via a collection of Dirac delta function sources [<xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R17">17</xref>]. Using data from [<xref ref-type="bibr" rid="R37">37</xref>] we found (see <xref ref-type="supplementary-material" rid="SD1">Supplementary material</xref>) that the depletion of T-DM1 from the blood stream can be modelled via an exponential function from data from [<xref ref-type="bibr" rid="R37">37</xref>] <disp-formula id="FD3"><label>(3)</label><mml:math id="M3"><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mtext>plasma</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mtext>plasma</mml:mtext></mml:mrow><mml:mrow><mml:mtext>initial</mml:mtext></mml:mrow></mml:msubsup><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>b</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:mspace width="1.2em"/><mml:mtext>where</mml:mtext><mml:mspace width="0.4em"/><mml:msubsup><mml:mi>C</mml:mi><mml:mrow><mml:mtext>plasma</mml:mtext></mml:mrow><mml:mrow><mml:mtext>initial</mml:mtext></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>810</mml:mn><mml:mtext>nM</mml:mtext><mml:mspace width="0.6em"/><mml:mtext>and</mml:mtext><mml:mspace width="0.6em"/><mml:mi>b</mml:mi><mml:mo>=</mml:mo><mml:mn>0.2105</mml:mn><mml:mspace width="0.2em"/><mml:msup><mml:mtext>day</mml:mtext><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></disp-formula></p><p id="P14"><xref ref-type="disp-formula" rid="FD2">Eq. (2)</xref> with plasma concentration depleting according to <xref ref-type="disp-formula" rid="FD3">Eq. (3)</xref> features six physical processes - diffusion, extravasation, plasma depletion, binding, unbinding and internalization - and each of these proceeds at an associated timescale. In our network, local vessel diameters <italic>d<sub>l</sub></italic> and inter-vessel distances <italic>h<sub>l</sub></italic> are in the ranges 15 − 110 and 100 − 1000 <italic>μ</italic>m, respectively. Using default parameters (as summarized in <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>), we can then estimate the values and ranges of the 6 timescales present in our simulations as follows: <disp-formula id="FD4"><mml:math id="M4"><mml:mn>2.36</mml:mn><mml:mspace width="0.2em"/><mml:mtext>day</mml:mtext><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>diff</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>h</mml:mi><mml:mi>l</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mi>D</mml:mi></mml:mfrac><mml:mo>&lt;</mml:mo><mml:mn>236</mml:mn><mml:mspace width="0.2em"/><mml:mtext>days</mml:mtext><mml:mspace width="1.2em"/><mml:mn>0.12</mml:mn><mml:mspace width="0.2em"/><mml:mtext>day</mml:mtext><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>ev</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>h</mml:mi><mml:mi>l</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mrow><mml:mi>π</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mi>P</mml:mi></mml:mrow></mml:mfrac><mml:mo>&lt;</mml:mo><mml:mn>87.7</mml:mn><mml:mspace width="0.2em"/><mml:mtext>day</mml:mtext><mml:mspace width="1.2em"/><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>pd</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi>b</mml:mi><mml:mo>=</mml:mo><mml:mn>4.75</mml:mn><mml:mspace width="0.2em"/><mml:mtext>day</mml:mtext></mml:math></disp-formula>
<disp-formula id="FD5"><mml:math id="M5"><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mi>ε</mml:mi><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mi>r</mml:mi></mml:msub><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>7.68</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:msup><mml:mspace width="0.2em"/><mml:mtext>day</mml:mtext><mml:mspace width="1.2em"/><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>7.82</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:msup><mml:mspace width="0.2em"/><mml:mtext>day</mml:mtext><mml:mspace width="1.2em"/><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>int</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>int</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>1.32</mml:mn><mml:mo>×</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mspace width="0.2em"/><mml:mtext>day</mml:mtext><mml:mo>.</mml:mo></mml:math></disp-formula></p><p id="P15">We see that the equilibration of diffusion, extravasation and plasma depletion processes happens much slower (days to months; note that standard T-DM1 treatments are administered in three-week cycles, i.e on the same timescale [<xref ref-type="bibr" rid="R37">37</xref>]) than that of kinetics (minutes), i.e. <disp-formula id="FD6"><mml:math id="M6"><mml:mi>min</mml:mi><mml:mspace width="0.2em"/><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>diff</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>ev</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>pd</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>≫</mml:mo><mml:mtext>max</mml:mtext><mml:mspace width="0.2em"/><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>int</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:math></disp-formula></p><p id="P16">Thus we propose a quasi-static model reduction whereby the equation for <italic>B</italic> is quasi-static (i.e. <italic>∂B/∂t</italic> ≈ 0). This means that <italic>B</italic> quasi-statically follows <italic>C</italic> according to <disp-formula id="FD7"><label>(4)</label><mml:math id="M7"><mml:mi>B</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:msub><mml:mi>C</mml:mi><mml:mi>r</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>ε</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>int</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mi>C</mml:mi><mml:mo>.</mml:mo></mml:math></disp-formula></p><p id="P17">Substituting this result back into the equation for <italic>C</italic>, we obtain <disp-formula id="FD8"><mml:math id="M8"><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mi>D</mml:mi><mml:msup><mml:mo>∇</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:mi>C</mml:mi><mml:mo>+</mml:mo><mml:mi>π</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mspace width="0.2em"/><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mtext>plasma</mml:mtext></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mfrac><mml:mi>C</mml:mi><mml:mi>ε</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mtext>network</mml:mtext></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>eff</mml:mtext></mml:mrow></mml:msub><mml:mi>C</mml:mi><mml:mo>,</mml:mo><mml:mspace width="1.2em"/><mml:mtext>where</mml:mtext><mml:mspace width="0.2em"/><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>eff</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>int</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:math></disp-formula> is the effective rate of the drug uptake. For the timescale of the effective uptake process we then have <disp-formula id="FD9"><mml:math id="M9"><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>eff</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>eff</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mrow><mml:mspace width="0.2em"/><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>int</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0.13</mml:mn><mml:mtext>day</mml:mtext><mml:mo>≪</mml:mo><mml:mi>min</mml:mi><mml:mrow><mml:mspace width="0.2em"/><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>diff</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>ev</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>pd</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:math></disp-formula> which holds true except for extreme combinations of very large local vessel diameter and very small inter-vessel distance. Thus, the distribution of the free drug on the timescale of interest (large times) follows from a linear quasi-static, which we refer to quasi-steady-state, reaction-diffusion equation <disp-formula id="FD10"><label>(5)</label><mml:math id="M10"><mml:mn>0</mml:mn><mml:mo>=</mml:mo><mml:mi>D</mml:mi><mml:msup><mml:mo>∇</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:mi>C</mml:mi><mml:mo>+</mml:mo><mml:mi>π</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mspace width="0.2em"/><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mtext>plasma</mml:mtext></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:mfrac><mml:mi>C</mml:mi><mml:mi>ε</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.2em"/><mml:msub><mml:mi>δ</mml:mi><mml:mrow><mml:mtext>network</mml:mtext></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>eff</mml:mtext></mml:mrow></mml:msub><mml:mi>C</mml:mi><mml:mo>,</mml:mo><mml:mspace width="0.7em"/><mml:mtext>where</mml:mtext><mml:msub><mml:mi>k</mml:mi><mml:mrow><mml:mtext>eff</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>on</mml:mtext></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>off</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mtext>int</mml:mtext></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:math></disp-formula> and <italic>C</italic><sub>plasma</sub> is given in <xref ref-type="disp-formula" rid="FD3">Eq. (3)</xref>. The bound-drug concentration <italic>B</italic> then follows from the quasi-steady-state assumption in <xref ref-type="disp-formula" rid="FD7">Eq. (4)</xref> and the internalized drug <italic>I</italic> is obtained simply by integrating the last equation in <xref ref-type="disp-formula" rid="FD2">Eq. (2)</xref>. Detailed derivations pertaining to the proposed model reduction are summarized in <xref ref-type="supplementary-material" rid="SD1">Supplementary material</xref>. Moreover, when posed on a simple geometry wherein a single cylindrical blood vessel perfuses the surrounding tissue, the reduced-order model is amenable to direct mathematical analysis - we found an exact solution to this problem and confirmed the validity of the model reduction via comparison with the numerical solution of the full problem - see <xref ref-type="supplementary-material" rid="SD1">Supplementary material</xref>. All dimensional parameters with appropriate units and references are summarized in <xref ref-type="supplementary-material" rid="SD1">Supplementary Table S1</xref>.</p></sec><sec id="S6"><title>Processing results</title><p id="P18">We define hypoxia as an oxygen concentration below 8 mmHg. We choose this value as it is defined as hypoxia in tumours [<xref ref-type="bibr" rid="R38">38</xref>], and because the efficacy of T-DM1 is reported to be reduced at that level of oxygenation [<xref ref-type="bibr" rid="R10">10</xref>]. Similarly, we determine that there is a sufficient concentration of T-DM1 when it is above the IC<sub>50</sub> (half maximum inhibitory concentration) reported in the literature, 2.9 nmol/L or 6.8 nmol/L, depending on the tumour cell line [<xref ref-type="bibr" rid="R10">10</xref>]. Therefore, there are two conditions required for optimal drug effect, which are a sufficiently high drug concentration, above the IC<sub>50</sub>, and a sufficient oxygen concentration, above the hypoxia limit, leading to four possible conditions at any point in the tissue: 1) <italic>C</italic><sub>T-DM1</sub> &gt; IC<sub>50</sub> and <italic>C</italic><sub><italic>o</italic>2</sub> &gt; <italic>C</italic><sub>hypoxia</sub>, 2) <italic>C</italic><sub>T-DM1</sub> &gt; IC<sub>50</sub> and <italic>C</italic><sub><italic>o</italic>2</sub> &lt; <italic>C</italic><sub>hypoxia</sub>, 3) <italic>C</italic><sub>T-DM1</sub> &lt; IC<sub>50</sub> and <italic>C<sub>o2</sub></italic> &gt; <italic>C</italic><sub>hypoxia</sub>, and 4) <italic>C</italic><sub>T-DM1</sub> &lt; IC<sub>50</sub> and <italic>C</italic><sub><italic>o</italic>2</sub> &lt; <italic>C</italic><sub>hypoxia</sub>.</p><p id="P19">The Student’s t-test is used to test if the difference in mean of two distributions is statistically significant. The null hypothesis of the test is that the mean of the two distributions is the same. If the null hypothesis is rejected, that is the p-value from the test is below 0.05, the two distributions have a different mean.</p><p id="P20">Two methods are used to quantify how well the drug and oxygen concentrations overlap. Firstly, the overlap index is used [<xref ref-type="bibr" rid="R39">39</xref>], <disp-formula id="FD11"><label>(6)</label><mml:math id="M11"><mml:mi>O</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mo>−</mml:mo><mml:mi>D</mml:mi><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:msub><mml:mi>O</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>,</mml:mo><mml:mi>y</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>max</mml:mi><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>T</mml:mi><mml:mo>−</mml:mo><mml:mi>D</mml:mi><mml:mi>M</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mi>max</mml:mi><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:msub><mml:mi>O</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:msub></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:math></disp-formula> where <italic>O</italic>(<italic>x, y</italic>) is the overlap index at position (<italic>x, y</italic>), <italic>C</italic><sub><italic>T−DM</italic>1</sub>(<italic>x, y</italic>) and <italic>CO<sub>2</sub></italic>(<italic>x,y</italic>) are the T-DM1 and oxygen concentrations at position (<italic>x, y</italic>), and max{<italic>C</italic><sub><italic>T −DM</italic>1</sub>} and max{<italic>C</italic><sub><italic>O</italic>2</sub>} are the maximum T-DM1 and oxygen concentrations in the tissue. The overlap index is bound between 0 and 1, where 0 means at least one of the two is absent, whereas 1 indicates both are present in their maximum quantities. Secondly, we use Moran’s Bivariate I to quantify the spatial correlation of oxygen with the drug, where Moran’s bivariate I is the correlation coefficient of a variable in space with the weighted average of the other variable in the neighbouring positions [<xref ref-type="bibr" rid="R40">40</xref>]. A Moran’s I of 0 indicates the two variables are uncorrelated, 1 that they are perfectly positively correlated, and -1 that they are perfectly negatively correlated [<xref ref-type="bibr" rid="R40">40</xref>].</p></sec></sec><sec id="S7" sec-type="results"><title>Results</title><sec id="S8"><title>Compression reduces tissue oxygenation</title><p id="P21">We start by investigating the effect that the tumour model (vessel compression) has on the fraction of hypoxic tissue. <xref ref-type="fig" rid="F2">Figure 2a–b</xref> shows heat maps for the oxygen concentration in the control model and tumour model, respectively. The heat maps reveal that, in the control model, most of the low oxygen concentration areas are due to avascular areas in the network. On the contrary, in the tumour model, one can see that the core region also has low oxygen concentration levels. In effect, in the core region the mean oxygen concentration falls from 10.85 mmHg (median 11.17 mmHg) to 6.24 mmHg (median 6.04 mmHg) in the tumour model, while the tumour model has a more heterogeneous oxygenation with an interquartile range of [3.62 mmHg, 8.33 mmHg] compared to the control model interquartile range of [9.77 mmHg, 12.30 mmHg]. In addition to the increased heterogeneity, the oxygen concentration interquartile range in the tumour model is entirely hypoxic (&lt; 8 mmHg), contrary to the control model. The distribution of oxygen concentrations in the tumour model and control model are plotted in <xref ref-type="fig" rid="F2">Figure 2d</xref>, showing a lower mean and wider distribution in the tumour model compared to the control model (difference is statistically significant).</p><p id="P22">We can observe from <xref ref-type="fig" rid="F2">Figure 2a–b</xref> that the periphery region of the tumour model also contains changes in the oxygenation compared to the control, particularly downstream of the compression. However, the mean oxygenation in the periphery of the control, 8.51 mmHg, is similar to that of the tumour model, 8.57 mmHg. The difference between the two distributions is statistically different, but the difference between the two means is 0.01 of a standard deviation, signifying the effect size is almost inexistent.</p><p id="P23">We next interrogate what fraction of the core region is hypoxic, defined as having an oxygen concentration below 8 mmHg of oxygen. In the control, the hypoxic fraction in the corw area is 11.5%, rising to 71.6% in the tumour model, representing a majority of the tissue. While in the periphery, the hypoxic fraction is similar in the control and in the tumour models, with the hypoxia being attributed to the aforementioned avascular areas. We hypothesise that the difference in hypoxic fraction between the control and the tumour models in the core region will reduce the efficacy of T-DM1, as T-DM1 is not as efficacious in hypoxic environments.</p></sec><sec id="S9"><title>Drug and oxygen overlap poorly and hypoxia reduces drug efficacy</title><p id="P24">Next, we investigate how the changed oxygenation of the tissue due to the tumour (compressed vessels) has an effect on the efficacy of T-DM1. <xref ref-type="fig" rid="F3">Figure 3a–b</xref> shows binary heat maps indicating where there is both sufficient oxygen and sufficient T-DM1 to have a good drug effect. The heat maps clearly show a reduced amount of tissue fraction having enough of both oxygen and T-DM1 in the tumour model, falling from 82% to 28% of the tissue, <xref ref-type="fig" rid="F3">Figure 3c–d</xref>. We further investigate if that change in T-DM1 efficacy is changed by the IC<sub>50</sub> value used, and the results, <xref ref-type="supplementary-material" rid="SD1">supplementary Figure S5</xref>, shows that the results with an IC<sub>50</sub> of 6.8 nM are similar to that of an IC<sub>50</sub> of 2.9 nM, <xref ref-type="fig" rid="F3">Figure 3</xref>.</p><p id="P25">We then investigate what is the cause of the poor effect of T-DM1 in the tissue. <xref ref-type="fig" rid="F3">Figure 3c–d</xref> breaks down the effect of the drug in the tissue into its four components (with respect to sufficient oxygen and sufficient T-DM1, see <xref ref-type="sec" rid="S2">methods</xref> for more details). It reveals that the loss in T-DM1 efficacy is mostly due to the insufficient oxygen for the T-DM1 to internalise properly, with 3% of the tissue in the control case having sufficient T-DM1 but insufficient oxygen, compared to 57% in the tumour case.</p><p id="P26">Finally, we use two metrics to calculate the spatial correlation of oxygen concentration and T-DM1 concentration, Moran’s bivariate I and the overlap index, see <xref ref-type="sec" rid="S2">methods</xref> for more details. In the control case, Moran’s bivariate I is 0.59, falling to 0.27. While the overlap index falls from a mean of 0.18±0.21 in the control case to 0.09±0.12 in the tumour model, the difference is statistically significant. The reduction in both Moran’s I and the overlap index illustrates that the tumour model, through compressing vessels, leads to a lower spatial correlation of oxygen concentration and drug concentration.</p></sec><sec id="S10"><title>The effect of inlet haematocrit and T-DM1 depletion from blood stream</title><p id="P27">One might speculate that the extent of hypoxia can simply be alleviated via increasing the inlet discharge haematocrit which could in turn improve the efficacy of T-DM1. In order to assess its impact on T-DM1 efficacy, in <xref ref-type="fig" rid="F4">Figure 4a–b</xref> we vary the inlet discharge haematocrit between 5 and 30%. Inlet discharge haematocrit below 15% is too low to produce sufficient oxygenation even in the close promixity of the blood vessels, independent of the compression status, which results in almost the entire tissue being hypoxic (<xref ref-type="fig" rid="F4">Figure 4a</xref>). Above this threshold, increasing inlet discharge haematocrit indeed yields an improved drug efficacy. However, while in the control case the efficacy improves greatly so that for 25-30% inlet discharge haematocrit, the majority of the tissue experiences sufficient concentrations of oxygen and T-DM1, the tumour model results in the majority of the tissue remaining inefficaciously perfused even for 30% inlet discharge haematocrit. The spatial correlation between oxygen and T-DM1, as evaluated by Moran’s I, only varies mildly as inlet discharge haematocrit is increased independent of tumour status (<xref ref-type="fig" rid="F4">Figure 4b</xref>). Therefore, the weak correlation observed when vessels are compressed cannot simply be rectified by increasing the inlet discharge haematocrit.</p><p id="P28">Motivated by the rate at which T-DM1 concentration in the blood stream decays, drug injections are standardly administered every 3 weeks [<xref ref-type="bibr" rid="R37">37</xref>] (see also <xref ref-type="supplementary-material" rid="SD1">Figure S1</xref>). <xref ref-type="fig" rid="F4">Figure 4c–d</xref> documents that due to the decay of T-DM1 from plasma, the efficacy of drug in the tissue decreases with time to a point where only a negligible fraction of the tissue experiences efficacious T-DM1, using two thresholding values – IC<sub>50</sub> = 2.9 nM (panel c) and IC<sub>50</sub> = 6.8 nM (panel d) – for two cell lines studied in [<xref ref-type="bibr" rid="R10">10</xref>]. Interestingly, in the tumour model when vessels are compressed, the fraction of tissue experiencing efficacious T-DM1 is low and essentially independent of the particular value of IC<sub>50</sub>. Confirming again that the primary factor preventing efficacious treatment is the prevalence of hypoxia caused by the tumour induced vessel compression.</p></sec></sec><sec id="S11" sec-type="discussion"><title>Discussion</title><p id="P29">The tumour microenvironment acts as a barrier to drug delivery and leads to tumour tissue hypoxia. In addition, some drugs require the presence of oxygen to be fully functional. We therefore hypothesised that the TME leads to areas of high drug concentration poorly overlapping with areas of high oxygen concentration due to their different modes of transport to tissue. In this work we tested this hypothesis with a computational model of a tumour with compressed tumour blood vessels, with oxygen and T-DM1 (an oxygen-dependent drug) transport from the blood vessels to the tissue, compared to a control model without compressed vessels.</p><p id="P30">We started by deriving a novel model reduction for T-DM1 transport based on key timescales, simplifying its numerical solution (it is worth noting that the model reduction derived in this work for T-DM1 might not be applicable for other drugs; this will always depend on the relevant timescales of transport and uptake processes [<xref ref-type="bibr" rid="R5">5</xref>]). We then simulated blood flow through tumour induced compression, and control, vessels which then acted as sources of both oxygen and T-DM1 to diffuse to the tissue. As the tumour compressed vessels introduce haematocrit heterogeneity in the microvascular networks, the tumour tissue oxygenation was found to be more heterogeneous than the control, with a hypoxic fraction increasing from 11.5% to 71.6%. We then showed that due to the higher fraction of hypoxia in the tumour tissue model, there is a lower fraction of efficacious T-DM1, 28% compared to 82% in a control model, as its internalisation is impeded in hypoxic conditions. This reduction in efficacious T-DM1 is the result of a reduced overlap of areas of high oxygen concentration with areas of high T-DM1 concentration. Finally, we showed that increasing the inlet discharge haematocrit to the network is insufficient to improve the efficacy of T-DM1 to levels comparable to that of a control.</p><p id="P31">One of the implications of this work is that independently considering oxygen transport and drug transport in oxygen dependent drugs can lead to lower drug efficacy than expected. Given that multiple important drugs, such as doxorubicin [<xref ref-type="bibr" rid="R11">11</xref>] and T-DM1 [<xref ref-type="bibr" rid="R10">10</xref>] amongst others [<xref ref-type="bibr" rid="R13">13</xref>], require the presence of oxygen to function, this work suggests that the overlap of drug and oxygen is an important biomarker for drug efficacy and therefore treatment outcome. We use tumour-induced vessel compression [<xref ref-type="bibr" rid="R27">27</xref>, <xref ref-type="bibr" rid="R41">41</xref>] and T-DM1 [<xref ref-type="bibr" rid="R37">37</xref>] as exemplars of a vascular abnormality and drug transport, and hypothesise that this effect would occur with other structural abnormalities; such as decreased inter-bifurcation length [<xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R20">20</xref>], increased tortuosity [<xref ref-type="bibr" rid="R42">42</xref>] and leakiness [<xref ref-type="bibr" rid="R43">43</xref>]; and other drugs with different transport properties [<xref ref-type="bibr" rid="R5">5</xref>].</p><p id="P32">Future work combining experimental validation and numerical modelling could enable one to predict what type of abnormalities present in a tumour microvascular network would lead to poor oxygen/drug overlap depending on the transport properties of a specific drug. One could then characterize the transport properties of microvascular networks via constructing governing dimensionless groupings which incorporate all key model parameters such as the vascular density, the inlet discharge haematocrit as well as other parameters determining the oxygen and drug perfusion (see [<xref ref-type="bibr" rid="R36">36</xref>] for the former and <xref ref-type="supplementary-material" rid="SD1">Table S1</xref> for the latter). We expect that this approach would provide more robust insights into drug efficacy assessment (e.g. a phase diagram dividing the parameter space into subregions where drug or oxygen perfusion limits the treatment efficacy) independent of a particular network design.</p><p id="P33">Finally, normalisation therapy offers a means of therapeutically changing tumour microvascular networks, with the aim of temporarily making them more efficient [<xref ref-type="bibr" rid="R44">44</xref>, <xref ref-type="bibr" rid="R45">45</xref>]. For example, angiotensin inhibition decompresses vessels and improves tissue oxygenation [<xref ref-type="bibr" rid="R44">44</xref>], through the opening of blocked vessels [<xref ref-type="bibr" rid="R44">44</xref>] and haematocrit homogenisation [<xref ref-type="bibr" rid="R18">18</xref>]. However, despite its promising approach, normalisation therapy has remained challenging [<xref ref-type="bibr" rid="R46">46</xref>]. This work postulates that normalisation could aim to improve drug and oxygen overlap, which could be tested experimentally, to improve therapeutic efficiency.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary material</label><media xlink:href="EMS199091-supplement-Supplementary_material.pdf" mimetype="application" mime-subtype="pdf" id="d17aAcEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S12"><title>Acknowledgments</title><p>M.O.B. gratefully acknowledges funding from: Fondation Leducq Transatlantic Network of Excellence (17 CVD 03); EPSRC grant no. EP/X025705/1; British Heart Foundation and The Alan Turing Institute Cardiovascular Data Science Award (C-10180357); Diabetes UK (20/0006221); Fight for Sight (5137/5138); the SCONe projects funded by Chief Scientist Office, Edinburgh &amp; Lothians Health Foundation, Sight Scotland, the Royal College of Surgeons of Edinburgh, the RS Macdonald Charitable Trust, and Fight For Sight; the Neurii initiative which is a partnership among Eisai Co., Ltd, Gates Ventures, LifeArc and HDR UK. J.B. was funded by the Medical Research Council Precision Medicine Doctoral Training Programme scholarships (MR/N013166/1).</p></ack><fn-group><fn id="FN3" fn-type="conflict"><p id="P34">Competing interests</p><p id="P35">All authors declare no competing interests.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Hallmarks of cancer: The next generation</article-title><year>2011</year><month>Mar</month><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewhirst</surname><given-names>MW</given-names></name><name><surname>Secomb</surname><given-names>TW</given-names></name></person-group><article-title>Transport of drugs from blood vessels to tumour tissue</article-title><source>Nature Reviews Cancer</source><year>2017</year><volume>17</volume><fpage>738</fpage><lpage>750</lpage><pub-id pub-id-type="pmcid">PMC6371795</pub-id><pub-id pub-id-type="pmid">29123246</pub-id><pub-id pub-id-type="doi">10.1038/nrc.2017.93</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stylianopoulos</surname><given-names>T</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><article-title>Combining two strategies to improve perfusion and drug delivery in solid tumors</article-title><source>Proceedings of the National Academy of Sciences</source><year>2013</year><volume>110</volume><fpage>18632</fpage><lpage>18637</lpage><pub-id pub-id-type="pmcid">PMC3832007</pub-id><pub-id pub-id-type="pmid">24167277</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1318415110</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewhirst</surname><given-names>MW</given-names></name><name><surname>Mowery</surname><given-names>YM</given-names></name><name><surname>Mitchell</surname><given-names>JB</given-names></name><name><surname>Cherukuri</surname><given-names>MK</given-names></name><name><surname>Secomb</surname><given-names>TW</given-names></name></person-group><article-title>Rationale for hypoxia assessment and amelioration for precision therapy and immunotherapy studies</article-title><source>Journal of Clinical Investigation</source><year>2019</year><month>Jan</month><volume>129</volume><fpage>489</fpage><lpage>491</lpage><pub-id pub-id-type="pmcid">PMC6355230</pub-id><pub-id pub-id-type="pmid">30614815</pub-id><pub-id pub-id-type="doi">10.1172/JCI126044</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thurber</surname><given-names>GM</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name></person-group><article-title>A systems approach for tumor pharmacokinetics</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><pub-id pub-id-type="pmcid">PMC3173470</pub-id><pub-id pub-id-type="pmid">21935441</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0024696</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minchinton</surname><given-names>AI</given-names></name><name><surname>Tannock</surname><given-names>IF</given-names></name></person-group><article-title>Drug penetration in solid tumours</article-title><year>2006</year><month>Aug</month><pub-id pub-id-type="pmid">16862189</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arvanitis</surname><given-names>CD</given-names></name><name><surname>Askoxylakis</surname><given-names>V</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Datta</surname><given-names>M</given-names></name><name><surname>Kloepper</surname><given-names>J</given-names></name><name><surname>Ferraro</surname><given-names>GB</given-names></name><name><surname>Bernabeu</surname><given-names>MO</given-names></name><name><surname>Fukumura</surname><given-names>D</given-names></name><name><surname>McDannold</surname><given-names>N</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><article-title>Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood–tumor barrier disruption</article-title><source>Proceedings of the National Academy of Sciences</source><year>2018</year><volume>115</volume><fpage>E8717</fpage><lpage>E8726</lpage><pub-id pub-id-type="pmcid">PMC6140479</pub-id><pub-id pub-id-type="pmid">30150398</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1807105115</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>d’Esposito</surname><given-names>A</given-names></name><name><surname>Sweeney</surname><given-names>PW</given-names></name><name><surname>Ali</surname><given-names>M</given-names></name><name><surname>Saleh</surname><given-names>M</given-names></name><name><surname>Ramasawmy</surname><given-names>R</given-names></name><name><surname>Roberts</surname><given-names>TA</given-names></name><name><surname>Agliardi</surname><given-names>G</given-names></name><name><surname>Desjardins</surname><given-names>A</given-names></name><name><surname>Lythgoe</surname><given-names>MF</given-names></name><name><surname>Pedley</surname><given-names>RB</given-names></name><name><surname>Shipley</surname><given-names>R</given-names></name><etal/></person-group><article-title>Computational fluid dynamics with imaging of cleared tissue and of in vivo perfusion predicts drug uptake and treatment responses in tumours</article-title><source>Nature Biomedical Engineering</source><year>2018</year><volume>2</volume><fpage>773</fpage><lpage>787</lpage><pub-id pub-id-type="pmid">31015649</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>RT</given-names></name><name><surname>Boucher</surname><given-names>Y</given-names></name><name><surname>Kozin</surname><given-names>SV</given-names></name><name><surname>Winkler</surname><given-names>F</given-names></name><name><surname>Hicklin</surname><given-names>DJ</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><article-title>Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors</article-title><source>Cancer Research</source><year>2004</year><volume>64</volume><fpage>3731</fpage><lpage>3736</lpage><pub-id pub-id-type="pmid">15172975</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandran</surname><given-names>VI</given-names></name><name><surname>Mansson</surname><given-names>AS</given-names></name><name><surname>Barbachowska</surname><given-names>M</given-names></name><name><surname>Cerezo-Magana</surname><given-names>M</given-names></name><name><surname>Nodin</surname><given-names>B</given-names></name><name><surname>Joshi</surname><given-names>B</given-names></name><name><surname>Koppa</surname><given-names>DAN</given-names></name><name><surname>Saad</surname><given-names>OM</given-names></name><name><surname>Gluz</surname><given-names>O</given-names></name><name><surname>Isaksson</surname><given-names>K</given-names></name><name><surname>Borgquist</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hypoxia attenuates trastuzumab uptake and trastuzumab-emtansine (T-DM1) cytotoxicity through redistribution of phosphorylated caveolin-1</article-title><source>Molecular Cancer Research</source><year>2020</year><month>Apr</month><volume>18</volume><fpage>644</fpage><lpage>656</lpage><pub-id pub-id-type="pmid">31900313</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osada-Oka</surname><given-names>M</given-names></name><name><surname>Kuwamura</surname><given-names>H</given-names></name><name><surname>Imamiya</surname><given-names>R</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Minamiyama</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Shiota</surname><given-names>M</given-names></name></person-group><article-title>Suppression of the doxorubicin response by hypoxia-inducible factor-1<italic>α</italic> is strictly dependent on oxygen concentrations under hypoxic conditions</article-title><source>European Journal of Pharmacology</source><year>2022</year><month>Apr</month><volume>920</volume><pub-id pub-id-type="pmid">35202675</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>JD</given-names></name><name><surname>Cabral</surname><given-names>H</given-names></name><name><surname>Stylianopoulos</surname><given-names>T</given-names></name><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><article-title>Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges</article-title><source>Nature Reviews Clinical Oncology</source><year>2020</year><month>Apr</month><volume>17</volume><fpage>251</fpage><lpage>266</lpage><pub-id pub-id-type="pmcid">PMC8272676</pub-id><pub-id pub-id-type="pmid">32034288</pub-id><pub-id pub-id-type="doi">10.1038/s41571-019-0308-z</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rebucci</surname><given-names>M</given-names></name><name><surname>Michiels</surname><given-names>C</given-names></name></person-group><article-title>Molecular aspects of cancer cell resistance to chemotherapy</article-title><year>2013</year><month>May</month><pub-id pub-id-type="pmid">23435357</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>D</given-names></name></person-group><article-title>Theoretical models of microvascular oxygen transport to tissue</article-title><source>Microcirculation</source><year>2008</year><volume>15</volume><fpage>795</fpage><lpage>811</lpage><pub-id pub-id-type="pmcid">PMC3057578</pub-id><pub-id pub-id-type="pmid">18608981</pub-id><pub-id pub-id-type="doi">10.1080/10739680801938289</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Secomb</surname><given-names>TW</given-names></name></person-group><article-title>Blood Flow in the Microcirculation</article-title><source>Annual Review of Fluid Mechanics</source><year>2017</year><volume>49</volume><fpage>443</fpage><lpage>461</lpage></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>RK</given-names></name><name><surname>Martin</surname><given-names>JD</given-names></name><name><surname>Stylianopoulos</surname><given-names>T</given-names></name></person-group><article-title>The Role of Mechanical Forces in Tumor Growth and Therapy</article-title><source>Annual Review of Biomedical Engineering</source><year>2014</year><volume>16</volume><fpage>321</fpage><lpage>346</lpage><pub-id pub-id-type="pmcid">PMC4109025</pub-id><pub-id pub-id-type="pmid">25014786</pub-id><pub-id pub-id-type="doi">10.1146/annurev-bioeng-071813-105259</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernabeu</surname><given-names>MO</given-names></name><name><surname>Köry</surname><given-names>J</given-names></name><name><surname>Grogan</surname><given-names>JA</given-names></name><name><surname>Markelc</surname><given-names>B</given-names></name><name><surname>Beardo</surname><given-names>A</given-names></name><name><surname>D’Avezac</surname><given-names>M</given-names></name><name><surname>Enjalbert</surname><given-names>R</given-names></name><name><surname>Kaeppler</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>N</given-names></name><name><surname>Hetherington</surname><given-names>J</given-names></name><name><surname>Krüger</surname><given-names>T</given-names></name><etal/></person-group><article-title>Abnormal morphology biases haematocrit distribution in tumour vasculature and contributes to heterogeneity in tissue oxygenation</article-title><source>Proceedings of the National Academy of Sciences</source><year>2020</year><volume>117</volume><fpage>27811</fpage><lpage>27819</lpage><pub-id pub-id-type="pmcid">PMC7668105</pub-id><pub-id pub-id-type="pmid">33109723</pub-id><pub-id pub-id-type="doi">10.1073/pnas.2007770117</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enjalbert</surname><given-names>R</given-names></name><name><surname>Krüger</surname><given-names>T</given-names></name><name><surname>Bernabeu</surname><given-names>MO</given-names></name></person-group><article-title>Effect of vessel compression on blood flow in microvascular networks and its implications for tumour tissue hypoxia</article-title><source>Communications Physics</source><year>2024</year><month>Feb</month><volume>7</volume></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enjalbert</surname><given-names>R</given-names></name><name><surname>Hardman</surname><given-names>D</given-names></name><name><surname>Krüger</surname><given-names>T</given-names></name><name><surname>Bernabeu</surname><given-names>MO</given-names></name></person-group><article-title>Compressed vessels bias red blood cell partitioning at bifurcations in a hematocrit-dependent manner: Implications in tumor blood flow</article-title><source>Proceedings of the National Academy of Sciences</source><year>2021</year><volume>118</volume><pub-id pub-id-type="pmcid">PMC8237689</pub-id><pub-id pub-id-type="pmid">34140409</pub-id><pub-id pub-id-type="doi">10.1073/pnas.2025236118</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merlo</surname><given-names>A</given-names></name><name><surname>Berg</surname><given-names>M</given-names></name><name><surname>Duru</surname><given-names>P</given-names></name><name><surname>Risso</surname><given-names>F</given-names></name><name><surname>Davit</surname><given-names>Y</given-names></name><name><surname>Lorthois</surname><given-names>S</given-names></name></person-group><article-title>A few upstream bifurcations drive the spatial distribution of red blood cells in model microfluidic networks</article-title><source>Soft Matter</source><year>2022</year><month>Feb</month><volume>18</volume><fpage>1463</fpage><lpage>1478</lpage><pub-id pub-id-type="pmid">35088062</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>JD</given-names></name><name><surname>Lanning</surname><given-names>RM</given-names></name><name><surname>Chauhan</surname><given-names>VP</given-names></name><name><surname>Martin</surname><given-names>MR</given-names></name><name><surname>Mousa</surname><given-names>AS</given-names></name><name><surname>Kamoun</surname><given-names>WS</given-names></name><name><surname>Han</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Stylianopoulos</surname><given-names>T</given-names></name><name><surname>Bawendi</surname><given-names>MG</given-names></name><name><surname>Duda</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition</article-title><source>Clinical Cancer Research</source><year>2022</year><month>July</month><volume>28</volume><fpage>3076</fpage><lpage>3090</lpage><pub-id pub-id-type="pmcid">PMC9355624</pub-id><pub-id pub-id-type="pmid">35584239</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-22-0486</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>SA</given-names></name><name><surname>Pigott</surname><given-names>KH</given-names></name><name><surname>Saunders</surname><given-names>MI</given-names></name><name><surname>Powell</surname><given-names>MEB</given-names></name><name><surname>Arnold</surname><given-names>S</given-names></name><name><surname>Obeid</surname><given-names>A</given-names></name><name><surname>Ward</surname><given-names>G</given-names></name><name><surname>Leahy</surname><given-names>M</given-names></name><name><surname>Hoskin</surname><given-names>PJ</given-names></name><name><surname>Chaplin</surname><given-names>DJ</given-names></name></person-group><article-title>Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes</article-title><source>British Journal of Cancer</source><year>1996</year><volume>74</volume><fpage>260</fpage><lpage>263</lpage><pub-id pub-id-type="pmcid">PMC2150022</pub-id><pub-id pub-id-type="pmid">8763893</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>H</given-names></name><name><surname>Braun</surname><given-names>R</given-names></name><name><surname>Ong</surname><given-names>E</given-names></name><name><surname>Hsu</surname><given-names>R</given-names></name><name><surname>Secomb</surname><given-names>T</given-names></name><name><surname>Papahadjopoulos</surname><given-names>D</given-names></name><name><surname>Hong</surname><given-names>K</given-names></name><name><surname>Dewhirst</surname><given-names>M</given-names></name></person-group><article-title>Flucuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma</article-title><source>Cancer Research</source><year>1996</year><volume>56</volume><fpage>5522</fpage><lpage>5528</lpage><pub-id pub-id-type="pmid">8968110</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michiels</surname><given-names>C</given-names></name><name><surname>Tellier</surname><given-names>C</given-names></name><name><surname>Feron</surname><given-names>O</given-names></name></person-group><article-title>Cycling hypoxia: A key feature of the tumor microenvironment</article-title><source>Biochimica et Biophysica Acta - Reviews on Cancer</source><year>2016</year><volume>1866</volume><fpage>76</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">27343712</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suwa</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Nam</surname><given-names>JM</given-names></name><name><surname>Harada</surname><given-names>H</given-names></name></person-group><article-title>Tumor microenvironment and radioresistance</article-title><year>2021</year><month>June</month><pub-id pub-id-type="pmcid">PMC8257724</pub-id><pub-id pub-id-type="pmid">34135469</pub-id><pub-id pub-id-type="doi">10.1038/s12276-021-00640-9</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimes</surname><given-names>DR</given-names></name><name><surname>Fletcher</surname><given-names>AG</given-names></name><name><surname>Partridge</surname><given-names>M</given-names></name></person-group><article-title>Oxygen consumption dynamics in steady-state tumour models</article-title><source>Journal of the Royal Society, Interface / the Royal Society</source><year>2014</year><volume>1</volume><pub-id pub-id-type="pmcid">PMC4448765</pub-id><pub-id pub-id-type="pmid">26064525</pub-id><pub-id pub-id-type="doi">10.1098/rsos.140080</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>L</given-names></name><name><surname>Xin</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name></person-group><article-title>Flattened microvessel independently predicts poor prognosis of patients with non-small cell lung cancer</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>30092</fpage><lpage>30099</lpage><pub-id pub-id-type="pmcid">PMC5444728</pub-id><pub-id pub-id-type="pmid">28404911</pub-id><pub-id pub-id-type="doi">10.18632/oncotarget.15617</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fredrich</surname><given-names>T</given-names></name><name><surname>Welter</surname><given-names>M</given-names></name><name><surname>Rieger</surname><given-names>H</given-names></name></person-group><article-title>Tumorcode: A framework to simulate vascularized tumors</article-title><source>European Physical Journal E</source><year>2018</year><month>Apr</month><volume>41</volume><pub-id pub-id-type="pmid">29700630</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rieger</surname><given-names>H</given-names></name><name><surname>Fredrich</surname><given-names>T</given-names></name><name><surname>Welter</surname><given-names>M</given-names></name></person-group><article-title>Physics of the tumor vasculature: Theory and experiment</article-title><source>European Physical Journal Plus</source><year>2016</year><month>Feb</month><volume>131</volume><fpage>1</fpage><lpage>24</lpage></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pries</surname><given-names>A</given-names></name><name><surname>Ley</surname><given-names>K</given-names></name><name><surname>Classen</surname><given-names>M</given-names></name><name><surname>Gaehtgens</surname><given-names>P</given-names></name></person-group><article-title>Red Cell Distribution at Microvascular</article-title><source>Microvascular research</source><year>1989</year><volume>38</volume><fpage>81</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">2761434</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pries</surname><given-names>AR</given-names></name><name><surname>Neuhaus</surname><given-names>D</given-names></name><name><surname>Gaehtgens</surname><given-names>P</given-names></name></person-group><article-title>Blood viscosity in tube flow: Dependence on diameter and hematocrit</article-title><source>American Journal of Physiology - Heart and Circulatory Physiology</source><year>1992</year><volume>263</volume><pub-id pub-id-type="pmid">1481902</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pries</surname><given-names>AR</given-names></name><name><surname>Secomb</surname><given-names>TW</given-names></name></person-group><article-title>Microvascular blood viscosity in vivo and the endothelial surface layer</article-title><source>American Journal of Physiology - Heart and Circulatory Physiology</source><year>2005</year><volume>289</volume><fpage>2657</fpage><lpage>2664</lpage><pub-id pub-id-type="pmid">16040719</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pries</surname><given-names>AR</given-names></name><name><surname>Secomb</surname><given-names>TW</given-names></name></person-group><article-title>Blood Flow in Microvascular Networks</article-title><source>Comprehensive Physiology Handbook of Physiology: Microcirculation</source><year>2008</year><fpage>1</fpage><lpage>34</lpage></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grogan</surname><given-names>JA</given-names></name><name><surname>Connor</surname><given-names>AJ</given-names></name><name><surname>Markelc</surname><given-names>B</given-names></name><name><surname>Muschel</surname><given-names>RJ</given-names></name><name><surname>Maini</surname><given-names>PK</given-names></name><name><surname>Byrne</surname><given-names>HM</given-names></name><name><surname>Pitt-Francis</surname><given-names>JM</given-names></name></person-group><article-title>Microvessel chaste: an open library for spatial modeling of vascularized tissues</article-title><source>Biophysical Journal</source><year>2017</year><volume>112</volume><fpage>1767</fpage><lpage>1772</lpage><pub-id pub-id-type="pmcid">PMC5425404</pub-id><pub-id pub-id-type="pmid">28494948</pub-id><pub-id pub-id-type="doi">10.1016/j.bpj.2017.03.036</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alarc’on</surname><given-names>T</given-names></name><name><surname>Byrne</surname><given-names>HM</given-names></name><name><surname>Maini</surname><given-names>PK</given-names></name></person-group><article-title>A cellular automaton model for tumour growth in inhomogeneous environment</article-title><source>Journal of theoretical biology</source><year>2003</year><volume>225</volume><fpage>257</fpage><lpage>274</lpage><pub-id pub-id-type="pmid">14575659</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owen</surname><given-names>MR</given-names></name><name><surname>Stamper</surname><given-names>IJ</given-names></name><name><surname>Muthana</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>GW</given-names></name><name><surname>Dobson</surname><given-names>J</given-names></name><name><surname>Lewis</surname><given-names>CE</given-names></name><name><surname>Byrne</surname><given-names>HM</given-names></name></person-group><article-title>Mathematical modeling predicts synergistic antitumor effects of combining a macrophage-based, hypoxia-targeted gene therapy with chemotherapy</article-title><source>Cancer Research</source><year>2011</year><month>Apr</month><volume>71</volume><fpage>2826</fpage><lpage>2837</lpage><pub-id pub-id-type="pmcid">PMC3527892</pub-id><pub-id pub-id-type="pmid">21363914</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2834</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girish</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Krop</surname><given-names>IE</given-names></name><name><surname>Vogel</surname><given-names>CL</given-names></name><name><surname>Burris</surname><given-names>HA</given-names></name><name><surname>LoRusso</surname><given-names>PM</given-names></name><name><surname>Yi</surname><given-names>JH</given-names></name><name><surname>Saad</surname><given-names>O</given-names></name><name><surname>Tong</surname><given-names>B</given-names></name><etal/></person-group><article-title>Clinical pharmacology of trastuzumab emtansine (T-DM1): An antibody-drug conjugate in development for the treatment of HER2-positive cancer</article-title><source>Cancer Chemotherapy and Pharmacology</source><year>2012</year><month>May</month><volume>69</volume><fpage>1229</fpage><lpage>1240</lpage><pub-id pub-id-type="pmcid">PMC3337408</pub-id><pub-id pub-id-type="pmid">22271209</pub-id><pub-id pub-id-type="doi">10.1007/s00280-011-1817-3</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKeown</surname><given-names>SR</given-names></name></person-group><article-title>Defining normoxia, physoxia and hypoxia in tumours - Implications for treatment response</article-title><source>British Journal of Radiology</source><year>2014</year><month>Mar</month><volume>87</volume><pub-id pub-id-type="pmcid">PMC4064601</pub-id><pub-id pub-id-type="pmid">24588669</pub-id><pub-id pub-id-type="doi">10.1259/bjr.20130676</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fall</surname><given-names>J</given-names></name><name><surname>Ciannelli</surname><given-names>L</given-names></name><name><surname>Skaret</surname><given-names>G</given-names></name><name><surname>Johannesen</surname><given-names>E</given-names></name></person-group><article-title>Seasonal dynamics of spatial distributions and overlap between Northeast Arctic cod (Gadus morhua) and capelin (Mallotus villosus) in the Barents Sea</article-title><source>PLoS ONE</source><year>2018</year><month>Oct</month><volume>13</volume><pub-id pub-id-type="pmcid">PMC6191152</pub-id><pub-id pub-id-type="pmid">30325964</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0205921</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anselin</surname><given-names>L</given-names></name><name><surname>Syabri</surname><given-names>S</given-names></name><name><surname>Smirnov</surname><given-names>O</given-names></name></person-group><article-title>Visualizing Multivariate Spatial Correlation with Dynamically Linked Windows</article-title><source>New Tools for Spatial Data Analysis: Proceedings of the Specialist Meeting</source><year>2002</year></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padera</surname><given-names>T</given-names></name><name><surname>Stoll</surname><given-names>B</given-names></name><name><surname>Tooredman</surname><given-names>J</given-names></name><name><surname>Capen</surname><given-names>D</given-names></name><name><surname>di Tomaso</surname><given-names>E</given-names></name><name><surname>Jain</surname><given-names>R</given-names></name></person-group><article-title>Cancer cells compress intratumour vessels</article-title><source>Nature</source><year>2004</year><volume>427</volume><fpage>695</fpage><pub-id pub-id-type="pmid">14973470</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penta</surname><given-names>R</given-names></name><name><surname>Ambrosi</surname><given-names>D</given-names></name></person-group><article-title>The role of the microvascular tortuosity in tumor transport phenomena</article-title><source>Journal of Theoretical Biology</source><year>2015</year><month>Jan</month><volume>364</volume><fpage>80</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">25218498</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azzi</surname><given-names>S</given-names></name><name><surname>Hebda</surname><given-names>JK</given-names></name><name><surname>Gavard</surname><given-names>J</given-names></name></person-group><article-title>Vascular permeability and drug delivery in cancers</article-title><source>Frontiers in Oncology</source><year>2013</year><month>AUG</month><volume>3</volume><pub-id pub-id-type="pmcid">PMC3744053</pub-id><pub-id pub-id-type="pmid">23967403</pub-id><pub-id pub-id-type="doi">10.3389/fonc.2013.00211</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>VP</given-names></name><name><surname>Martin</surname><given-names>JD</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Lacorre</surname><given-names>DA</given-names></name><name><surname>Jain</surname><given-names>SR</given-names></name><name><surname>Kozin</surname><given-names>SV</given-names></name><name><surname>Stylianopoulos</surname><given-names>T</given-names></name><name><surname>Mousa</surname><given-names>AS</given-names></name><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Adstamongkonkul</surname><given-names>P</given-names></name><name><surname>Popović</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels</article-title><source>Nature Communications</source><year>2013</year><volume>4</volume><pub-id pub-id-type="pmcid">PMC3806395</pub-id><pub-id pub-id-type="pmid">24084631</pub-id><pub-id pub-id-type="doi">10.1038/ncomms3516</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><article-title>Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy</article-title><source>Science</source><year>2005</year><volume>307</volume><fpage>58</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15637262</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>RK</given-names></name></person-group><article-title>Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers</article-title><source>Journal of Clinical Oncology</source><year>2013</year><volume>31</volume><fpage>2205</fpage><lpage>2218</lpage><pub-id pub-id-type="pmcid">PMC3731977</pub-id><pub-id pub-id-type="pmid">23669226</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2012.46.3653</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pries</surname><given-names>AR</given-names></name><name><surname>Secomb</surname><given-names>TW</given-names></name><name><surname>Gaehtgens</surname><given-names>P</given-names></name><name><surname>Gross</surname><given-names>JF</given-names></name></person-group><article-title>Blood flow in microvascular networks. Experiments and simulation</article-title><source>Circulation research</source><year>1990</year><fpage>826</fpage><lpage>834</lpage><pub-id pub-id-type="pmid">2208609</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorthois</surname><given-names>S</given-names></name><name><surname>Cassot</surname><given-names>F</given-names></name><name><surname>Lauwers</surname><given-names>F</given-names></name></person-group><article-title>Simulation study of brain blood flow regulation by intra-cortical arterioles in an anatomically accurate large human vascular network: Part I: Methodology and baseline flow</article-title><source>NeuroImage</source><year>2011</year><month>Jan</month><volume>54</volume><fpage>1031</fpage><lpage>1042</lpage><pub-id pub-id-type="pmid">20869450</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poon</surname><given-names>KA</given-names></name><name><surname>Flagella</surname><given-names>K</given-names></name><name><surname>Beyer</surname><given-names>J</given-names></name><name><surname>Tibbitts</surname><given-names>J</given-names></name><name><surname>Kaur</surname><given-names>S</given-names></name><name><surname>Saad</surname><given-names>O</given-names></name><name><surname>Yi</surname><given-names>J-H</given-names></name><name><surname>Girish</surname><given-names>S</given-names></name><name><surname>Dybdal</surname><given-names>N</given-names></name><name><surname>Reynolds</surname><given-names>T</given-names></name></person-group><article-title>Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability</article-title><source>Toxicology and applied pharmacology</source><year>2013</year><volume>273</volume><fpage>298</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">24035823</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bordeau</surname><given-names>BM</given-names></name><name><surname>Abuqayyas</surname><given-names>L</given-names></name><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Balthasar</surname><given-names>JP</given-names></name></person-group><article-title>Development and Evaluation of Competitive Inhibitors of Trastuzumab-HER2 Binding to Bypass the Binding-Site Barrier</article-title><source>Frontiers in Pharmacology</source><year>2022</year><month>Feb</month><volume>13</volume><pub-id pub-id-type="pmcid">PMC8895951</pub-id><pub-id pub-id-type="pmid">35250584</pub-id><pub-id pub-id-type="doi">10.3389/fphar.2022.837744</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><p>(a) Illustration of microvascular network generated with Tumorcode [<xref ref-type="bibr" rid="R28">28</xref>], see <xref ref-type="sec" rid="S2">methods</xref> for more details. The black arrows indicate the inlet, at the bottom left, and the outlet, at the top right. In red are the core vessels (compressed in the tumour model) and in blue are the periphery vessels. (b) Illustration of a diverging vessel bifurcation showing key equations of the presented model at the microscale, the red blood cells are for illustration purposes as they are not individually resolved in our model. The equations and their variables are defined in <xref ref-type="sec" rid="S2">Methods</xref> section and the <xref ref-type="supplementary-material" rid="SD1">supplementary material</xref>.</p></caption><graphic xlink:href="EMS199091-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>(a) and (b) show tissue oxygenation in mmHg for the control model (a) and the tumour model (b), the dashed circle delineates the core and periphery regions. (c) shows the fraction of hypoxic tissue in each model, in the core and periphery regions. (d) shows violin plots for each model, in the core and periphery regions, dashed line is the hypoxia limit at 8mmHg.</p></caption><graphic xlink:href="EMS199091-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>(a) Shows efficacious T-DM1 (oxygen above 8mmHg and T-DM1 above 2.9 nM, both required for internalisation and killing cells, respectively) in control simulation. (b) Shows efficacious T-DM1 in tumour simulation. (c) Shows fraction of tissue in core region corresponding to sufficient/insufficient oxygen/T-DM1 in control (c) and tumour (d) cases.</p></caption><graphic xlink:href="EMS199091-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p>(a) shows how increasing inlet discharge haematcorit changes the fraction of high oxygen/high T-DM1 in the tissue. (b) shows how Moran’s I changes with inlet discharge haematocrit. (c) shows efficacy of T-DM1 with time when IC<sub>50</sub> = 2.9 nM. (d) shows efficacy of T-DM1 with time when IC<sub>50</sub> = 6.8 nM.</p></caption><graphic xlink:href="EMS199091-f004"/></fig></floats-group></article>